TheraLife warning letter
This article was originally published in The Tan Sheet
FDA says claims for TheraLife's Wrist, Fatigue, Neck and Back & Leg products classify them as unapproved new drugs and are misleading. The products make drug claims such as, "Treats painful and chronic conditions often experienced by computer keyboard and mouse users," according to FDA. On its Web site, the firm also says it adheres to all FDA regulatory guidelines and provides a link to FDA's 30-day structure/function claims. FDA says the company is not in compliance and is misleading by linking to FDA's site. TheraLife has 15 days to correct the violations, the agency says...
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.